One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First Mover Advantage and a Well-Recognized Brand.
Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties.
Capital-Efficient and Flexible Operating Model with Disciplined Expansion.
Delivering High-Quality Clinical Care Through Renowned Clinicians, Supported with Modern Equipment.
Digital Technology Enabling Clinical Effectiveness, Patient Experience and Operational Efficiencies.
Doctor-Led Professional Management Team with Proven Execution Capabilities.
The Company has incurred losses during the three months period ended June 30, 2025 and Fiscals 2025 and 2024 of Rs. (10.24) million, Rs. (579.83) million and Rs. (153.31) million, respectively, on a consolidated basis. While the company were profitable in the three months period ended June 30, 2026 and Fiscal 2026, its cannot assure you that the company will continue to remain profitable in the future.
The company's Subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited have collectively incurred a loss of Rs. (203.82) million, Rs. (520.89) million, Rs. (822.38) million and Rs. (872.69) million during the three months period ended June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. Its cannot assure you that these Subsidiaries will turn profitable in the future.
The company is highly dependent on doctors, nurses, other healthcare professionals and housekeeping and support staff for its operations. The company has experienced high attrition rates of 12.01%, 16.09%, 60.38%, 66.74% and 65.27% in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If the company is unable to reduce or manage the attrition rates of these professionals, its business, results of operations and financial condition may be adversely affected.
Five of the company's eight hospitals are located in North India. In the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, the revenue from these hospitals accounted for 68.07%, 66.89%, 66.07%, 68.40% and 67.33% of its revenue from operations, respectively. Any adverse developments affecting these hospitals or the regions in which they are located could affect the company's business, results of operations and financial condition.
The name of one of the members of our Promoter Group, Harbaksh Singh Khangura appears in the CIBIL wilful defaulter database, and there is no guarantee that his name will be removed from the CIBIL defaulter database or that he will not be subject to any adverse proceedings or rulings in the future.
We generate a significant portion of our revenue from the provision of cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports injury and renal sciences (collectively, "CONGOR") specialties, which contributed 74.35%, 75.30%, 74.70%, 71.92% and 72.34% of our revenue from operations in the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, respectively. Any adverse developments in the demand for such services could adversely affect our business, results of operations and financial condition.
The provision of healthcare services involves high costs such as employee benefit expenses, retainers and consultants fee and purchases of stock-in-trade, which together accounted for 66.13%, 64.40%, 65.08%, 63.69% and 66.95% of our total expenses in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If we fail to pass on these costs to patients, our business, results of operations and financial condition could be adversely affected.
We conduct the operations of six of our eight hospitals on leased premises. We operate certain hospitals through revenue share arrangements and long-term leases, and we operate one hospital pursuant to a public-private partnership arrangement. Any adverse developments in our relationships with our lessors or counterparties, or our inability to renew such arrangements, could adversely affect our business, financial condition and results of operations.
We have certain contingent liabilities that have been disclosed in our financial statements, which if they materialize, may adversely affect our results of operations, cash flows and financial condition. Our contingent liabilities, as of June 30, 2026, constituted 89.55% of our net worth.
There are outstanding litigations against our Company, Subsidiaries, Promoter, Directors, Key Managerial Personnel and Senior Management, and there were certain regulatory and statutory proceedings initiated against our Promoter and Directors in the past. Any adverse decision in such proceedings, or similar instances in the future may render us or them liable for penalties, and may adversely affect our business, cash flows and reputation.
